期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗结核药的研究进展与临床评价

Research Progress and Clinical Evaluation of Anti-tuberculosis Drugs
下载PDF
导出
摘要 目的:介绍已进入临床试验阶段或较有希望的几类抗结核新药,并对抗结核药的发展方向做简单介绍。方法:收集国内外近期相关文献进行分析评价。结果与结论:抗结核新药的研发目前正处于快速上升阶段,不久的将来这些新药可能会用于结核病的治疗。 OBJECTIVE：To introduce several new antituberculosis drugs which have been put to use in clinical trial and the antituberculosis drugs with promising future and the development direction of antituberculosis drugs.METHODS：We reviewed the recent pertinent literature both at home and abroad.RESULTS CONCLUSION：The development of antituberculosis drugs is rapid and prosperous and it is expected that these drugs will be used to treat tuberculosis in the near future.
作者 赵伟杰 郭振勇
机构地区 北京市结核病胸部肿瘤研究所 北京胸科医院
出处 《中国医院用药评价与分析》 2010年第8期679-681,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 抗结核 新药 评价 进展 Antituberculosis New drugs Evaluation Progress
分类号 R978.3 [医药卫生—药品]
  • 相关文献

参考文献24

  • 1Cohn J. Medicine. New TB drug promises shorter, simpler treatment [ J ]. Science,2004,306 ( 5703 ) : 1872.
  • 2Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [ J ]. Science, 2005, 307 (14) :223.
  • 3Nacer Lounis, Nicolas Veziris, Aurelie Chauffour, et al. Combination of R207910 with drugs used to treat muhidrug- resistant tuberculosis have the potential to shorten treatment duration [ J ]. Antimicrob Agents Chemother, 2006,50 ( 11 ) : 3543.
  • 4Lounis N, Guillemont J, Veziris N, et al. R207910 (TMC207): A new antibiotic for the treatment of tuberculosis [ J ]. Med Mal Infect, 2010,40 ( 7 ) : 383.
  • 5Lenaerts AJ, Cruppo V, Marietta KS, et al. Preclinical testing of nitroimidazopyran PA - 824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models [ J ]. Antimicrob Agents Chemother, 2005,49 (6) :2294.
  • 6Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA - 824 in a murine model of tuberculosis [ J ]. Antimicrob Agents Chemother, 2005,49 ( 6 ) : 2289.
  • 7Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability and pharmacokinetics of PA - 824 in healthy subjects [ J ]. Antimicrob Agents Chemther, 2009, 53 (9) :3720.
  • 8Matsumoto M, Hashizume H, Tomishige T,et al. OPC - 67683, a nitro - dihydro - imidazooxazole derivative with promising action against tuberculosis in vitro and in mice [J]. PLoSMed, 2006,3(11):e466.
  • 9Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxaein - containing regimen greatly reduces time to culture conversion in murine tuberculosis [J]. Am J Respir Crit Care Med, 2004,169 (3) :421.
  • 10Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxaein - containing regimens of reduced duration produce a stable cure in murine tuberclosis [ J]. Am J Respir Crit Care Med, 2004, 170(10) :1131.

二级参考文献37

  • 1A. Fernández-Villar,B. Sopena,J. Fernández-Villar,R. Vázquez-Gallardo,F. Ulloa,V. Leiro,M. Mosteiro,L. Pineiro,马玙.抗结核药物肝毒性反应的危险因素及其影响[J].结核与肺部疾病杂志,2005,8(1):28-34. 被引量：13
  • 2Daphne Yee,Chantal Valiquette,Marthe Pelletier,et al.Incidence of side effects from first-line antituberculosis drugs among patients treated for active tuberculosis[J].Am J Respir Crit Care Med,2003,167(11):1 461.
  • 3Okuyan B,Izzettin FV,Sancar M,et al.Effect of antituberculous drugs on human polymorphonuclear leukocyte functions in vitro[J].Int Immunopharmacol,2005,5 (7-8):1 337.
  • 4Solangi GA,Zuberi BF,Shaikh S,et al.Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy[J].J Coll Physicians Surg Park,2004,14(3):136.
  • 5Shin SS,Hvson AM,Castaned C,et al.Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis[J].Int J Tuberc Lung Dis,2003,7(4):347.
  • 6MorganrothJ,Talbt GH,Dorr MB,et al.Effect of single ascending,supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval)[J].Clin Ther,1999,21(5):818.
  • 7汪复,张婴元.抗结核分枝杆菌及非结核分枝杆菌药见:实用抗感染治疗学[M].第1版.北京:人民卫生出版社,2004:337.
  • 8李拯民,明安宇.抗结核药物及其副反应[M].北京:中国防痨协会,1989:19.
  • 9贾公孚,谢惠民.抗结核药物见:药物联用禁忌手册[M].第2版.北京:中国协和医科大学出版社,2001:96.
  • 10Klemens S P,Cynamon M H.Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model[J].Antimicrob Agents Chemother,1995,39(10):2295

共引文献8

中国医院用药评价与分析
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部